Results 121 to 130 of about 287,761 (311)
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel +12 more
wiley +1 more source
Among the waiting models proposed in the literature most of them focus on homogeneous arrival rate. This paper proposes a single server waiting line with modulated arrival rate of small and large size of traffic sources.
Raghavendran. R, V. Vidhya
doaj +1 more source
Modelling Joint Lifetimes of Couples by Using Bivariate Phase-type\n Distributions [PDF]
Amin Hassan Zadeh, Soroush Amirhashchi
openalex +1 more source
PHASE-TYPE DISTRIBUTIONS FOR CLAIM SEVERITY REGRESSION MODELING [PDF]
Martin Bladt
openalex +1 more source
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
A joint likelihood approach to the analysis of length of stay data utilising the continuous-time hidden Markov model and Coxian phase-type distribution [PDF]
Hannah Mitchell +2 more
openalex +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Dynamic change in the distribution of cancer types in oncology phase I trials
Junya Sato +6 more
openalex +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source

